Praxis Precision Medicines
PRAX | NASDAQ
$310.27
-$17.86 (-5.44%)
At close: Nov 16, 2026, 4:00 PM ET
$312.14
+$1.87 (+0.60%)
After-hours:
Nov 16, 2026, 7:31 PM ET
Praxis Precision Medicines Company Profile
Company profile explainedCompany Profile
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Marcio Souza | President, Chief Executive Officer & Director |
| Kelly McCue | Chief People Officer |
| Megan T. Sniecinski | Chief Operating Officer |
| Timothy Edwin Kelly | Chief Financial Officer & Treasurer |
| Alex Nemiroff | General Counsel & Secretary |
| Alyssa J. S. Wyant | Chief Regulatory & Quality Officer |
| Brian Spar | Chief of Staff |
| Karl Hansen | Chief Technical Operations Officer |
| Orrin Devinsky | Head of Clinical Strategy |
| Steven Petrou | Co-Founder and President of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 08, 2026 | 4 | Filing |
| Jul 07, 2026 | 8-K | Current Report |
| Jul 02, 2026 | 8-K | Current Report |
| Jun 29, 2026 | 8-K | Current Report |
| Jun 26, 2026 | 4 | Filing |
| Jun 24, 2026 | 144 | Filing |
| Jun 22, 2026 | 8-K | Current Report |
Praxis Precision Medicines
| Country | United States |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Marcio Silva De'Souza |
Contact Details
99 High Street Boston,
Massachusetts 02110 United States
Stock Details
| Ticker Symbol | PRAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001689548 |
| CUSIP Number | 74006W207 |
| ISIN Number | US74006W2070 |
| SIC Code | 2834 |
Recent News
- 15 hours ago / seekingalpha.comPraxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript
- 21 hours ago / seekingalpha.comPraxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)
- 5 days ago / seekingalpha.comPraxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
- 8 days ago / globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- 20 days ago / globenewswire.comPraxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
- 3 months ago / seekingalpha.comPraxis: Commercial Launch Could Smash Expectations (Video)
- 3 months ago / seekingalpha.comPraxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
- 3 months ago / marketbeat.comPraxis Precision Medicines Q2 Earnings Call Highlights
- 4 months ago / globenewswire.comPraxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- 4 months ago / seekingalpha.comPraxis Precision Medicines: Priced For Half Of What I Think It's Worth
Add to Watchlist
Select watchlists to add or remove PRAX